SpaceX去年收入150-160亿美元、利润约80亿，而预计的IPO估值超过1.5万亿美元

Group 1 - The core financial data reveals that SpaceX achieved revenues between $15 billion and $16 billion last year, with an EBITDA profit of approximately $8 billion, prompting investment banks to reassess its IPO potential [1] - Several banks now estimate that SpaceX's valuation at IPO could exceed $1.5 trillion, with a fundraising scale potentially surpassing $50 billion, making it one of the largest IPOs globally [1] - The company plans to go public later this year, targeting a date around Elon Musk's 55th birthday on June 28 [1] Group 2 - SpaceX's profitability is heavily concentrated in its Starlink satellite internet system, which contributes approximately 50% to 80% of the company's revenue [2] - Since 2019, SpaceX has launched around 9,500 satellites and has over 9 million users, establishing itself as the largest satellite operator globally [2] - The stable cash flow generated by Starlink supports commercial expansion and is a core funding source for the ongoing development of the Starship heavy rocket [2] Group 3 - Despite approaching the IPO window, SpaceX continues to expand, including discussions about a potential merger with Musk's AI company xAI [3] - The company also invested $19 billion to acquire wireless spectrum resources from EchoStar to advance its direct-to-device satellite communication business [3] - This initiative aims to extend Starlink services to allow mobile devices to connect directly to Starlink satellites without specialized terminals [3] Group 4 - These strategic moves are seen as efforts by SpaceX to further solidify its leading position in the satellite internet sector before going public [4] Group 5 - Elon Musk anticipates that Starship will begin executing commercial payload launch missions this year, having completed 11 test launches since 2023 [5] - In the long term, Starship is envisioned for deploying space AI data centers, closely related to the proposed merger with xAI, although this concept remains in its early and high-risk stages [5]